clofibric acid has been researched along with fibrinogen in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 13 (59.09) | 18.2507 |
| 2000's | 8 (36.36) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davidson, JF; Lorimer, AR; Simpson, IA; Walker, ID | 1 |
| Krüger, B | 1 |
| Almeida Pinto, LE; Cendoroglo, MS; da Rocha Martinez, TL; Duarte, M; Fonseca, FA; Novazzi, JP; Rabelo, LM | 1 |
| Graham, MJ; Gray, TJ; Old, SL; Winham, MA | 1 |
| de Valois, JC; Kastelein, JJ; Knipscheer, HC; van den Ende, B; Wouter ten Cate, J | 1 |
| Athyros, VG; Boudoulas, H; Hatzikonstandinou, HA; Kontopoulos, AG; Mayroudi, MC; Papageorgiou, AA | 1 |
| de Maat, MP; Kastelein, JJ; Kluft, C; Knipscheer, HC | 1 |
| de Maat, MP; Kastelein, JJ; Kluft, C; Knipscheer, HC; Kockx, M; Kooistra, T; Princen, HM | 1 |
| Kockx, M; Kooistra, T; Princen, HM | 1 |
| Byrne, DJ; Ganotakis, ES; Jagroop, IA; Mikhailidis, DP; Spyropoulos, KA; Winder, AF | 1 |
| Derudas, B; Gervois, PP; Gonzalez, FJ; Kockx, M; Kooistra, T; Peters, JM; Poulain, P; Princen, HM; Staels, B | 1 |
| Chelstowski, K; Jastrzebska, M; Kopciewicz, J; Naruszewicz, M; Pieczul-Mróz, J; Torbus-Lisiecka, B | 1 |
| Bernat, A; Chatenet-Duchène, L; Herbert, JM | 1 |
| Cibulova, L; Fedelesova, V; Gajdos, M; Huttova, D; Krivosikova, Z; Mongiellova, V; Polak, F | 1 |
| Balogh, Z; Paragh, G | 1 |
| Ascaso, JF; Carmena, R; Hernández-Mijares, A; Lluch, I; Martínez-Triguero, ML; Vizcarra, E | 1 |
| Aguilar-Salinas, CA; Fanghänel-Salmón, G; Gómez Pérez, FJ; González-Valdez, H; Gulías-Herrero, A; Meza, E; Monterrubio-Flores, EA; Montes, J; Sánchez, L | 1 |
| Cibulová, L; Dzúrik, R; Gajdos, M; Huttová, D; Krivosíková, Z; Mongiellová, V; Spustová, V | 1 |
| Cwalina, L; Herman, ZS; Kalina, Z; Kowalski, J; Lebek, M; Okopien, B; Wisniewska-Wanat, M; Zielinski, M | 1 |
| Bairaktari, E; Elisaf, M; Ganotakis, E; Mikhailidis, DP; Rizos, E; Tsimihodimos, V | 1 |
| Arocha-Piñango, CL; Carvajal, Z; Castillo, L; Espinosa, RA; Gil, A; Lundberg, U; Mijares, ME; Nagy, E; Rodríguez-Larralde, A; Rodríguez-Roa, E | 1 |
| Broncel, M | 1 |
2 review(s) available for clofibric acid and fibrinogen
| Article | Year |
|---|---|
[Effect of fibrates on lipid metabolism and the blood coagulation system].
Topics: Arteriosclerosis; Blood Coagulation; Clofibric Acid; Fibrinogen; Hemostasis; Humans; Lipid Metabolism; Peroxisome Proliferators | 2000 |
[Fibrates and markers of inflammation].
Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Cytokines; Fibrinogen; Humans; Hypolipidemic Agents; Inflammation; Interleukin-6; Metabolic Networks and Pathways; PPAR alpha | 2007 |
11 trial(s) available for clofibric acid and fibrinogen
| Article | Year |
|---|---|
Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
Topics: Adult; Aged; Clofibric Acid; Double-Blind Method; Female; Fibric Acids; Fibrinogen; Follow-Up Studies; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Retrospective Studies | 1996 |
Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
Topics: Adult; Analysis of Variance; Clofibric Acid; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Fibric Acids; Fibrinogen; Follow-Up Studies; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Morbidity; Prospective Studies; Safety; Simvastatin; Survival Rate; Treatment Outcome; Ultracentrifugation | 1996 |
Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
Topics: Adult; Clofibric Acid; Female; Fibric Acids; Fibrinogen; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged | 1997 |
Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
Topics: Adult; Aged; Cholesterol; Clofibric Acid; Double-Blind Method; Female; Fibric Acids; Fibrinogen; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Smoking; Tissue Plasminogen Activator; Treatment Outcome | 1997 |
Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Diabetes Mellitus, Type 1; Factor VII; Fibrinogen; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pilot Projects; Risk Factors; Statistics, Nonparametric | 1999 |
Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.
Topics: Adult; Aged; Apolipoproteins B; Area Under Curve; Arteriosclerosis; Blood Glucose; Carbohydrate Metabolism; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibric Acids; Fibrinogen; Glycated Hemoglobin; Humans; Hypolipidemic Agents; Lipid Metabolism; Lipoprotein(a); Male; Middle Aged; Triglycerides | 2000 |
Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Topics: Adolescent; Adult; Aged; Apolipoproteins B; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diet; Female; Fibric Acids; Fibrinogen; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Triglycerides | 2001 |
Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
Topics: Aged; Arteriosclerosis; Aspirin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Fibrinogen; Fibrinolytic Agents; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet-Derived Growth Factor | 2001 |
Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Fibrinogen; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Thrombosis; Tissue Plasminogen Activator; Treatment Outcome; Triglycerides | 2001 |
Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
Topics: Analysis of Variance; Cholesterol; Clofibric Acid; Female; Fibric Acids; Fibrinogen; Humans; Hyperlipidemias; Kidney; Lipoproteins; Liver; Male; Statistics, Nonparametric; Triglycerides | 2002 |
[Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
Topics: Adolescent; Adult; Aged; Cholesterol; Clofibric Acid; Coronary Artery Disease; Female; Fibric Acids; Fibrinogen; Hemostasis; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pilot Projects; Prospective Studies; Triglycerides | 2006 |
9 other study(ies) available for clofibric acid and fibrinogen
| Article | Year |
|---|---|
Effect of Ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia.
Topics: Adult; Alkaline Phosphatase; Cholesterol; Clofibrate; Clofibric Acid; Fibric Acids; Fibrinogen; Fibrinolysis; Humans; Hypercholesterolemia; Male; Middle Aged; Platelet Aggregation; Platelet Count | 1985 |
Etofibrate therapy and effect of added low-dose cholestyramine in patients with combined hyperlipidaemia.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibric Acid; Drug Synergism; Drug Therapy, Combination; Female; Fibrinogen; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoprotein(a); Male; Middle Aged; Practice Guidelines as Topic; Triglycerides | 1994 |
[Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate].
Topics: Adult; Clofibric Acid; Female; Fibrinogen; Humans; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Platelet Aggregation | 1996 |
Comparative hypolipidaemic and peroxisomal effects of ciprofibrate, clofibric acid, and their respective difluorocyclopropyl and 4-fluoro-substituted analogues in rat.
Topics: Animals; Cholesterol; Clofibric Acid; Dose-Response Relationship, Drug; Fibric Acids; Fibrinogen; Hypolipidemic Agents; Liver; Male; Microbodies; Microscopy, Electron; Organ Size; Oxidation-Reduction; Rats; Rats, Inbred F344; Triglycerides | 1996 |
Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Alitretinoin; Animals; Apolipoprotein A-I; Cells, Cultured; Clofibrate; Clofibric Acid; Dimerization; Female; Fenofibrate; Fibric Acids; Fibrinogen; Gemfibrozil; Gene Expression Regulation; Genes, Reporter; Hypolipidemic Agents; Liver; Macaca fascicularis; Male; Peroxisome Proliferators; Plasminogen Activator Inhibitor 1; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Transcription Factors; Transcriptional Activation; Tretinoin | 1998 |
Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.
Topics: Body Weight; Cardiovascular Diseases; Clofibric Acid; Female; Fibric Acids; Fibrinogen; Humans; Hyperlipidemias; Hypolipidemic Agents; Life Style; Lipoproteins; Liver Function Tests; Male; Middle Aged; Retrospective Studies; Risk Factors | 1998 |
Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha.
Topics: Animals; Cells, Cultured; Clofibrate; Clofibric Acid; DNA-Binding Proteins; Fenofibrate; Fibric Acids; Fibrinogen; Gene Expression Regulation; Hypolipidemic Agents; Kinetics; Liver; Male; Mice; Mice, Knockout; Peroxisome Proliferators; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors; Transcription, Genetic; Triglycerides | 1999 |
Effect of ciprofibrate on fibrinogen synthesis in vitro on hepatoma cells and in vivo in genetically obese Zucker rats.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Clofibric Acid; Dose-Response Relationship, Drug; Drug Antagonism; Fibric Acids; Fibrinogen; Humans; Hypolipidemic Agents; Interleukin-6; Liver Neoplasms; Obesity; Oncostatin M; Peptides; Rats; Rats, Zucker; Tumor Cells, Cultured | 1999 |
[The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
Topics: Aged; Arteriosclerosis; Aspirin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Fibrinogen; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Platelet Aggregation Inhibitors; Thromboxane B2 | 1999 |